Skip to content

Clinical Therapeutics

ISSN 1879-114X

5 papers in the library · 3 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Physical Activity Level Moderates Cannabis-Associated Reductions in Negative Affect in Anxious Individuals.

Clinical Therapeutics September 2026 Jonathon K. Lisano, Luiza Rosa, Greg Giordano et al.

Emerging research indicates that the use of cannabis products, particularly those higher in cannabidiol (CBD), may be anxiolytic. Physical activity is another modality observed to have anxiolytic effects. Despite evidence of cannabis and physical activity being paired together, there is limited research on the possible synergistic effects of physical activity and cannabis use on reductions in...

Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders

Clinical Therapeutics June 1, 2026 Anna Luiza Guimarães, Fernando R. Beserra, Lucas Cruz et al.

PURPOSE: The interest in psychedelics for health-related purposes has grown significantly over the past decade. However, there is an insufficient representation of stakeholders (eg, Indigenous groups, activists, policymakers) in discussions about research and regulation. Many psychedelics originate from traditional practices historically developed in low- and middle-income countries, but these...

DOI: 10.1016/j.clinthera.2026.05.012 (opens in new tab) Stakeholder Relevance law Indigenous Thematic analysis +8

Early-Onset Cannabis Use, Retinal Biomarkers, and Risk for Schizophrenia Preliminary Study.

Clinical Therapeutics May 1, 2026 D. Valenti, Holly Kailher

PURPOSE Cannabis remains one of the most commonly used psychoactive substances among adolescents, with increasing prevalence of daily use during formative neurodevelopmental years. This preliminary study looks at changes in low spatial frequency contrast sensitivity perception using frequency doubling virtual reality technology (IMMAD-FDT). Early initiation of cannabis use-particularly before...

Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.

Clinical Therapeutics March 1, 2025 Lisa Harding, Maryia Zhdanava, Amanda Teeple et al. 3 citations

Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. Data on health care resource use (HRU) and costs among patients with MDSI initiated on esketamine nasal spray relative to traditional treatments are limited. This study sought to describe HRU and medical costs of patients with MDSI initiated on...

DOI: 10.1016/j.clinthera.2024.12.006 (opens in new tab) Full text (opens in new tab) Acute care Antidepressant Health care costs Suicidal ideation +5

The Impact of Cannabis Use on Adolescent Neurodevelopment and Clinical Outcomes Amidst Changing State Policies.

Clinical Therapeutics June 1, 2023 J. Ross, Sharona T. Levy

Cannabis is the most common illicit substance used by adolescents and the third most common psychoactive substance after alcohol and nicotine. Cannabis use during adolescence interrupts a critical period of brain development and leads to inappropriate activation of the reward pathway. Because the prefrontal cortex, which is responsible for impulse control and other executive functions, is not...